NDA 208090 · Collegium Pharm INC
Xtampza Er
Oxycodone · Oral · Opioid Agonist
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 26, 2016
Approved uses
2
Original approval plus efficacy supplements
Registered trials
646
137 Phase 3, 50 recruiting
FAERS reports
108,968
83,817 serious, 24,820 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF XTAMPZA ER WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF XTAMPZA ER See full prescribing information for complete boxed warning . XTAMPZA ER exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.1 ) Serious, life-threatening, or fatal respiratory depression may occur especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of XTAMPZA ER are essential. ( 5.2 ) Accidental ingestion of XTAMPZA ER, especially by children, can result in fatal overdose of oxycodone. ( 5.2 ) Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in...
What it is approved for
From the label in effect Dec 30, 2025.
XTAMPZA ER is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. XTAMPZA ER is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death,which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including XTAMPZA ER, for use in patients for whom alternative treatment optionsare ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) XTAMPZA ER is not indicated as an as-needed (prn) analgesic. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ], reserve opioid analgesics, including XTAMPZA ER, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. XTAMPZA ER is not indicated as an as-needed (prn) analgesic.
Mechanism: Oxycodone is a full opioid agonist and is relatively selective for the mu receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 6, 2017 Supplement 4 · Efficacy LabelLetterReview
- Apr 26, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelOtherReview
5 products under this application
- XTAMPZA ER · OXYCODONE 18MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- XTAMPZA ER · OXYCODONE 9MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- XTAMPZA ER · OXYCODONE 27MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- XTAMPZA ER · OXYCODONE 13.5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- XTAMPZA ER · OXYCODONE 36MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxycodone" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Opioid Prescription After Cesarean TrialPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT04296396 · 5,521 participants · Start Sep 21, 2020 · Primary completion Apr 7, 2022
Drug: 0 to 20 tablets of oxycodone 5mg; Fixed opioid prescription · For: Pregnancy Related; Opioid Use; Pain
Sites: Birmingham, Alabama; Chicago, Illinois; New York, New York · 12 sites in all
- Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer PainPivotal-lookingCompleted
Gachon University Gil Medical CenterAcademic, hospital or other
NCT00478101 · 2,006 participants · Start Feb 2006
Drug: oxycodone fentanyl · For: Advanced Solid Cancers
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Determining the Effect of an "Alternate Recovery Protocol" Versus Current Standard of Care After Cesarean SectionPivotal-lookingTerminated
Brest, Norman A., M.D.Academic, hospital or other
NCT03330119 · 1,494 participants · Start Oct 4, 2017 · Primary completion Jun 20, 2018
Drug: Alternate Management; Control · For: Pregnancy Related; Narcotic Use
Sites: Wynnewood, Pennsylvania
- Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Post-operative PainPivotal-lookingNot yet recruiting
Ailin LuoAcademic, hospital or other
NCT06721988 · 1,316 participants (planned) · Start Jan 1, 2025 · Primary completion Dec 31, 2026
Drug: oxycodone and parecoxib sodium combinations; Placebo and parecoxib sodium combinations · For: Oxycodone; Chronic Pain, Postoperative
- A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00361504 · 1,123 participants · Start Nov 2006 · Primary completion Jul 2008
Drug: Oxycodone CR; Tapentadol (CG5503) ER · For: Osteoarthritis, Hip; Osteoarthritis, Knee; Lower Back Pain and 1 more
Sites: Mesa, Arizona; Tucson, Arizona; Anaheim, California · 52 sites in all
- Comparative Effectiveness Study for Surgery vs. Non-Surgery in Patients With Low Back PainPivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02883569 · 1,102 participants · Start Sep 2016 · Primary completion Dec 2020
Drug: ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac; codeine, oxycontine, IRcodone, Tramadol · For: Low Back Pain
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain11,316
- fatigue9,976
- drug ineffective9,424
- nausea8,498
- off label use7,127
- diarrhoea6,890
- death6,704
- dyspnoea6,514
- rash6,278
- arthralgia6,169
- vomiting6,157
- headache5,710
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 225 |
| 2005 | 342 |
| 2006 | 287 |
| 2007 | 66 |
| 2008 | 215 |
| 2009 | 918 |
| 2010 | 1,403 |
| 2011 | 1,232 |
| 2012 | 1,680 |
| 2013 | 3,893 |
| 2014 | 5,008 |
| 2015 | 7,649 |
| 2016 | 7,268 |
| 2017 | 7,796 |
| 2018 | 8,859 |
| 2019 | 9,014 |
| 2020 | 9,376 |
| 2021 | 9,074 |
| 2022 | 9,048 |
| 2023 | 7,206 |
| 2024 | 6,827 |
| 2025 | 6,975 |
| 2026 | 4,606 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xtampza ER (Oxycodone Myristate)
2024 spending
$233M
Beneficiaries
50,981
371,096 claims
Per beneficiary
$4,565
$11.04 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $161,277,680 |
| 2021 | $240,889,559 |
| 2022 | $259,804,241 |
| 2023 | $250,042,795 |
| 2024 | $232,750,637 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.
Kistemaker KRJ, Sijani F, Brinkman DJ, et al. · Cancer Treat Rev 2024 · Meta-Analysis, Systematic Review
- Acute Postoperative Pain Due to Dental Extraction in the Adult Population: A Systematic Review and Network Meta-analysis.
Miroshnychenko A, Ibrahim S, Azab M, et al. · J Dent Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Shifting Views on Cancer Pain Management: A Systematic Review and Network Meta-Analysis.
Imkamp MSV, Theunissen M, Viechtbauer W, et al. · J Pain Symptom Manage 2024 · Systematic Review, Network Meta-Analysis
- Tapentadol and oxycodone reduce cingulate glutamate in healthy volunteers.
Hansen TM, Frøkjaer JB, Mark EB, et al. · Br J Clin Pharmacol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of oxycodone for postoperative dental pain: A systematic review and meta-analysis.
Teoh L, McCullough M, Taing MW · J Dent 2022 · Meta-Analysis, Systematic Review
- Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology.
Oliveira RAA, Baptista AF, Sá KN, et al. · Arq Neuropsiquiatr 2020 · Meta-Analysis, Systematic Review
Sponsor: Collegium Pharm INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.